We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+0.63%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$6.11B
AUM Growth
+$207M
Cap. Flow
+$183M
Cap. Flow %
2.99%
Top 10 Hldgs %
49.09%
Holding
188
New
51
Increased
37
Reduced
33
Closed
43

Top Sells

Rank Stock Value
1
FIVE icon
Five Below
FIVE
+$67.4M
2
PTCT icon
PTC Therapeutics
PTCT
+$64.3M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$61.2M
4
BURL icon
Burlington
BURL
+$60.4M
5
ROST icon
Ross Stores
ROST
+$42.3M

Sector Composition

Rank Sector Weight
1 Healthcare 42.67%
2 Consumer Discretionary 7.86%
3 Consumer Staples 7.27%
4 Technology 5.96%
5 Communication Services 1.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OLB icon
126
OLB
OLB
$4.44M
$1.39M 0.02%
+52,251
New +$2.39M
TRVI icon
127
Trevi Therapeutics
TRVI
$2.65B
$1.18M 0.02%
+1,512,344
New +$1.59M
BXRX
128
DELISTED
Baudax Bio, Inc. Common Stock
BXRX
$1.02M 0.02%
+3,335
New +$2.09M
NERV icon
129
Minerva Neurosciences
NERV
$203M
$820K 0.01%
128,000
+3,000
+2% +$28.2K
SWAGW icon
130
Stran & Company Warrant
SWAGW
$108K
$616K 0.01%
+545,000
New +$577K
ROI
131
DELISTED
RiskOn International, Inc. Common Stock
ROI
$602K 0.01%
8,996
-36,699
-80% -$3.89M
GROY.WS
132
DELISTED
Gold Royalty Corp. Warrants, each warrant exercisable for one common share at an exercise price of $7.50
GROY.WS
$448K 0.01%
448,000
NRSNW icon
133
NeuroSense Therapeutics Warrant
NRSNW
$2.76M
$388K 0.01%
+425,000
New +$379K
GROMW
134
DELISTED
Grom Social Enterprises Inc. Warrants
GROMW
$375K 0.01%
24,100
KTTAW icon
135
Pasithea Therapeutics Warrants
KTTAW
$21.4K
$370K 0.01%
1,000,000
DBGIW
136
DELISTED
Digital Brands Group, Inc. Warrant
DBGIW
$369K 0.01%
7,229
GMVDW
137
DELISTED
G Medical Innovations Holdings Ltd. Warrants
GMVDW
$300K ﹤0.01%
1,000,000
CINGW icon
138
Cingulate Inc Warrants
CINGW
$31.8K
$291K ﹤0.01%
+410,000
New +$301K
SBEV.WS
139
DELISTED
Splash Beverage Group, Inc. Warrants to purchase 1/40th of a share of Common Stock at an exercise price of $184.00
SBEV.WS
$280K ﹤0.01%
904,000
MDGSW
140
DELISTED
Medigus Ltd. Series C Warrant
MDGSW
$270K ﹤0.01%
1,285,715
AGRIW
141
DELISTED
AgriFORCE Growing Systems Ltd Warrant
AGRIW
$264K ﹤0.01%
600,000
NLSPW
142
DELISTED
NLS Pharmaceutics Warrant
NLSPW
$250K ﹤0.01%
500,000
DRMAW icon
143
Dermata Therapeutics Warrant
DRMAW
$16.3K
$140K ﹤0.01%
325,000
PETVW
144
DELISTED
PetVivo Holdings, Inc. Warrant
PETVW
$114K ﹤0.01%
200,000
SQLLW
145
DELISTED
SeqLL Inc. Warrant
SQLLW
$42K ﹤0.01%
50,000
AMZN icon
146
Amazon
AMZN
$2.94T
-230,000
Closed -$37.8M
BABA icon
147
Alibaba
BABA
$308B
-100,000
Closed -$14.8M
BBY icon
148
Best Buy
BBY
$17.8B
-324,182
Closed -$34.3M
BMBL icon
149
Bumble
BMBL
$397M
-212,000
Closed -$10.6M
BURL icon
150
Burlington
BURL
$23.2B
-212,994
Closed -$60.4M

Similar funds

Armistice Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Armistice Capital held 188 positions worth $6.11B, up 3.5% from $5.9B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Armistice Capital's Q4 2021 filing shows 51 new, 37 increased, 33 reduced and 43 closed positions. Its largest new stake was AutoZone: 38,024 shares worth $79.7M. The largest sale was Five Below, an estimated $67.4M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, down from 45% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

  • Armistice Capital's largest Q4 2021 buy was AutoZone: 38,024 shares worth $79.7M.
  • Armistice Capital added most to Jazz Pharmaceuticals in Q4 2021, an estimated $72.8M increase.
  • Armistice Capital's biggest Q4 2021 reduction was PTC Therapeutics, cutting an estimated $64.3M.
  • Armistice Capital fully exited Five Below in Q4 2021, selling an estimated $67.4M.
  • Armistice Capital's ten largest holdings make up 49% of its $6.11B portfolio in Q4 2021.
  • Armistice Capital opened 51 new positions and closed 43 in Q4 2021.
  • Armistice Capital's portfolio value rose 3.5% quarter-over-quarter to $6.11B.

Based on Armistice Capital's 13F filing for Q4 2021, filed 14 Feb 2022.